Corners of the immunotherapy space are getting crowded. Is that a problem? – STAT
STAT |
Corners of the immunotherapy space are getting crowded. Is that a problem?
STAT here's an overabundance of copycat drugs in the cancer immunotherapy space, with companies pouring millions into developing drugs that only add incremental value to patients. That was the general consensus from a panel of biotech experts who spoke … |
